Trials / Completed
CompletedNCT04693234
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tislelizumab | 200 mg administered intravenously once every 3 weeks on day 1 of each cycle |
| BIOLOGICAL | Ociperlimab | 900 mg administered intravenously once every 3 weeks on day 1 of each cycle |
Timeline
- Start date
- 2021-02-15
- Primary completion
- 2022-06-16
- Completion
- 2023-08-31
- First posted
- 2021-01-05
- Last updated
- 2025-04-27
- Results posted
- 2025-04-27
Locations
68 sites across 8 countries: Bulgaria, China, Poland, Russia, South Korea, Taiwan, Thailand, Ukraine
Source: ClinicalTrials.gov record NCT04693234. Inclusion in this directory is not an endorsement.